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Abstract: To date, it remains unknown which patients report a clinically-relevant improvement in
fatigue following pulmonary rehabilitation (PR). The purpose of this study was to identify and
characterize these responders. Demographics, lung function, anxiety (anxiety subscale of the 90-item
symptom checklist (SCL-90-A)), depression (Beck depression inventory for primary care (BDI-PC)),
exercise tolerance (six-minute walking distance test (6MWD)), and health status (Nijmegen clinical
screening instrument (NCSI)) were assessed before and after a 12-week PR programme. Fatigue was
assessed using the checklist individual strength (CIS)-Fatigue. Patients with a decline ≥ 10 points
(minimally clinically important difference, MCID) on the CIS-Fatigue were defined as responders.
Chronic obstructive pulmonary disease (COPD) patients (n = 446, 61 ± 9 years, 53% male, forced
expiratory volume in 1 s (FEV1) 43% ± 18% predicted, 75% severe fatigue) were included. Mean
change in fatigue after PR was 10 ± 12 points (p < 0.01) and exceeded the MCID. In total, 56%
were identified as fatigue responders. Baseline CIS-Fatigue (45 ± 7 vs. 38 ± 9 points, respectively,
p < 0.001) and health-related quality-of-life (HRQoL; p < 0.001) were different between responders
and non-responders. No differences were found in demographics, baseline anxiety, depression,
lung function, 6MWD, and dyspnoea (p-values > 0.01). Responders on fatigue reported a greater
improvement in anxiety, depression, 6MWD, dyspnoea (all p-values < 0.001), and most health status
parameters. PR reduces fatigue in COPD. Responders on fatigue have worse fatigue and HRQoL
scores at baseline, and are also likely to be responders on other outcomes of PR.
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1. Introduction
Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease,
which is characterized by persistent airflow limitation [1]. Most COPD-related studies only focus on
respiratory-related symptoms (i.e., dyspnoea, and to a lesser extent also phlegm, wheezing, cough,
and/or chest tightness) [2]. Nevertheless, more than half of the patients with COPD suffer from severe
fatigue [3]. This extra-pulmonary symptom is defined as “the subjective feeling of tiredness, exhaustion
or lack of energy, that occurs on a daily basis” [4]. Severe fatigue may have a substantial impact
on functional impairment, physical activity, and quality of life (QoL) in patients with COPD [3,5–7],
and is often described as invalidating, and results in care dependency [8]. Furthermore, fatigue is
also related with mortality [9], morbidity, exacerbation-related hospitalization, and length of hospital
stay [10,11]. Therefore, reducing fatigue has been put forward by patients as one of the priorities for
respiratory research [12]. A four-year observational study on fatigue in patients with COPD reported
that severe fatigue doubled in patients with mild to severe COPD despite optimal COPD care [13].
Hence, patients need more than just standard COPD treatment to improve fatigue. Nowadays more
complex patients with a high symptom burden and multiple limitations (during daily living) are
referred to a multidisciplinary pulmonary rehabilitation (PR) programme [14], which is defined as
“a comprehensive intervention based on a thorough patient assessment followed by patient-tailored
therapies which include, but are not limited to, exercise training, education, and behaviour change,
designed to improve the physical and psychological condition of people with chronic respiratory
disease and to promote the long-term adherence of health-enhancing behaviours” [15]. PR has shown
positive effects on daily symptoms of dyspnoea, exercise tolerance, and QoL in patients with COPD [16].
Houben-Wilke and colleagues recently showed that the item ‘energy’ of the COPD assessment test
(CAT) improves with the greatest effect size after PR [17]. A single CAT item, however, is too limited
to truly assess the impact of PR on fatigue. A common multi-dimensional scale to evaluate fatigue
is the subjective fatigue subscale of the checklist individual strength (CIS-Fatigue) [18]. Peters and
colleagues already reported a significant mean improvement in CIS-Fatigue score following 12-week
of PR in patients with COPD [19]. However, it remains unknown which patients show a clinically
relevant improvement in fatigue. The aims of this study were (1) to determine the proportion and
characteristics of COPD patients with a clinically relevant improvement in fatigue scores following PR;
(2) to assess the impact of PR in responders and non-responders on fatigue; and (3) its relation with
change in possible contributing factors to fatigue.
2. Methods
2.1. Study Design and Participants
A secondary analysis of data, prospectively collected at the start and the end of a pulmonary
rehabilitation (PR) programme at the University Lung Centre Dekkerswald of the Radboud University
Medical Center (Radboudumc; Nijmegen, The Netherlands), was conducted [19]. Chest physicians
referred these outpatients to PR because of a persistent high symptom burden, problems in activities
of daily living, difficulties to cope with/adapt to their disease or a combination of these, despite
optimal COPD care. Eligibility criteria were (1) diagnosis of COPD based on the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) with a post-bronchodilator forced expiratory volume in
1 s (FEV1) to forced vital capacity (FVC) ratio < 0.7 [1], (2) completion of the 12-week PR programme,
(3) pre-PR data available regarding gender, age, weight, and lung function (to determine diagnosis
of COPD and reference values), and (4) pre- and post-PR data available regarding subjective fatigue
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(checklist individual strength-fatigue; CIS-Fatigue). The Medical Ethical Committee of the Radboudumc
approved this retrospective study of data collected during usual care (reference: 2018-4994).
2.2. Pulmonary Rehabilitation
Patients underwent a 12-week (five day/week) inpatient multidisciplinary PR programme as
part of usual care. Eight disciplines (pulmonologist, psychologist, physiotherapist, nurse, dietician,
psychomotor therapist, social worker, and enhanced art therapist) were involved in the PR programme.
Based upon comprehensive health status assessments and clinical interviews by seven disciplines (the
art therapist did not participate in the PR assessment), individual goals were set for the PR programme.
This multidisciplinary and individualized treatment programme consisted of a training programme,
education sessions, group therapy, and individual therapy, as described in the American Thoracic
Society (ATS) and European Respiratory Society (ERS) statement regarding PR [15]. Every three weeks,
the treatment progress was evaluated by representatives of the eight disciplines and with the patient.
If needed, the treatment programme was adapted.
2.3. Assessments and Questionnaires
Demographical, clinical, and health status features were assessed during the comprehensive
baseline assessment. These assessments and clinical interviews were distributed over two consecutive
days, and took place four weeks prior to the start of the PR programme on average.
2.3.1. Demographical Features
The following demographical data were systematically registered at baseline: age, gender, weight,
height, tobacco use (non-/ex-/smoker), time since COPD diagnosis (≤ 10/> 10 years), self-reported
comorbidities, and education level. The latter was classified in three groups: high, middle, and low
based upon the Dutch classification system according to Verhage [20].
2.3.2. Clinical Features
Body composition was measured as fat free mass index (FFMi; kg/m2) by bio-electrical impedance
analysis (BIA) and body mass index (BMI; kg/m2). BMI was calculated and classified in four subgroups:
underweight (BMI < 21) [21], normal weight (21 ≤ BMI < 25), overweight (25 ≤ BMI < 30), and obese
(BMI ≥ 30) [22]. Lung function was evaluated with post-bronchodilator spirometry according to
the ATS/ERS guidelines. Based upon the degree of airflow limitation, patients were classified into
four subgroups (GOLD stages): GOLD grade I (FEV1 ≥ 80% predicted), GOLD grade II (50 ≤ FEV1
< 80% predicted), GOLD grade III (30 ≤ FEV1 < 50% predicted), and GOLD grade IV (FEV1 < 30%
predicted) [1]. Exercise tolerance was measured using a six-minute walking distance test (6MWD)
according to ERS/ATS technical standards [23]. The reference values for healthy elderly subjects
established by Troosters and colleagues were used to express the distance as a percentage of the
predicted value [24]. A score of < 70% predicted was used to classify patients as having an ‘impaired
exercise tolerance’ [25]. An improvement of 30 m or more was defined as the minimally clinically
important difference (MCID) [23,26]. The quadriceps muscle strength of both legs (maximal isometric
muscle force of the knee extensors) was measured using a handheld dynamometer (MicroFET2,
Biometrics, Almere, The Netherlands). The highest value was reported. The anxiety subscale of
the 90-item symptom checklist (SCL-90-A) was used to measure generalized anxiety in addition to
dyspnoea-specific anxiety, which is measured with the Nijmegen clinical screening instrument (NCSI;
sub-domain dyspnoea emotions). The SCL-90-A is a self-reported questionnaire and consists of 10
questions on a five-point scale ranging from 1 (‘not at all’) to 5 points (‘extremely’) [27,28]. The
SCL-90-A scores range from 10 to 50 points, and a higher score indicates more clinical symptoms of
anxiety. A score of ≥ 23 points was used to classify patients as having a ‘level of anxiety more than
average’ [29,30].
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2.3.3. Health Status and Clinical Features Obtained via NCSI
The health status of patients was assessed using the NCSI. The NCSI is an empirically-composed
battery of existing instruments (including the CIS-Fatigue, Beck depression index for primary care,
dyspnoea visual analogue scale, sickness impact scale, and others), such that health status is measured
in detail by a minimum of items [31]. The NCSI measures 24 aspects of health status that for
research purposes are aggregated into the following eight subdomains: subjective dyspnoea, dyspnoea
emotions, subjective fatigue, subjective impairment, behavioural impairment, general quality of life
(QoL), health-related quality of life (HRQoL), and satisfaction with relations. Table 1 shows the
instruments measuring each sub-domain. A higher score on a subdomain of the NCSI indicates a
worse health status on the corresponding subdomain [32].
Table 1. Definitions and instruments of the sub-domains of the Nijmegen clinical screening
instrument (NCSI).
Domain Sub-Domain Definition Instruments/Measurement Items
Symptoms
Subjective
dyspnoea
The patient’s overall burden of
pulmonary symptoms
PARS-D global dyspnea activity [31]
PARS-D global dyspnea burden [31] 2
Dyspnoea
emotions
The level of frustration and
anxiety a person experiences
when dyspnoeic
DEQ frustration [31]
DEQ anxiety [31] 6
Fatigue The level ofexperienced fatigue CIS subjective fatigue [18] 8
Functional
impairment
Subjective
impairment
The experienced degree of
impairment in general QoLRiQ general activities [33,34] 4
Behavioural
impairment
The extent to which a person
cannot perform specific and
concrete activities as a result of
having the disease
SIP home management [35]
SIP ambulation [35] 22
Quality of life
General QoL
Mood and the satisfaction of a
person with his/her life as
a whole
BDI for primary care [36]
Satisfaction with life scale [37] 12
HRQoL Satisfaction related to physicalfunctioning and the future
Satisfaction physiological
functioning [31]
Satisfaction future [31]
2
Satisfaction
relations
Satisfaction with the (absent)
relationships with spouse
and others
Satisfaction spouse [31]
Satisfaction social [31] 2
Abbreviations: PARS-D, physical activity rating scale-dyspnea; DEQ, dyspnea emotions questionnaire; CIS, checklist
individual strength; QolRiQ, quality of life for respiratory illness questionnaire; QoL, quality of life; HRQoL,
health-related quality of life; SIP, sickness impact profile; BDI, Beck depression inventory.
Subjective fatigue was measured by the subjective fatigue subscale of the CIS-Fatigue [18]. The
CIS-Fatigue is a standardized and validated questionnaire that has been used in healthy subjects [38]
and among various patient populations [39,40], such as COPD [3,31]. The CIS-Fatigue consists of
eight items scored on a seven-point Likert scale. Scores range from 8 to 56 points. A score of ≤ 26
points indicates normal fatigue, scores between 27 and 35 points indicate mild fatigue, and a score
of ≥ 36 points indicates severe fatigue [18,41]. The MCID of the CIS-Fatigue in patients with COPD
is 10 points [13]. Based on the MCID of the CIS-Fatigue, responders and non-responders on fatigue
were classified. Patients with a decline ≥ 10 points on the CIS-Fatigue following PR were defined as
responders. Patients with a decline < 10 points were defined as non-responders.
The global dyspnoea burden of patients over the past four weeks was scored using the dyspnoea
visual analogue scale (dyspnoea VAS) at the comprehensive baseline assessment four weeks prior to
the start of the PR programme. Patients indicated the shortness of breath they felt most days during
the past four weeks. Scores of the dyspnoea VAS range from 0 (‘no breathlessness’) to 10 points (‘worst
breathlessness possible’) [31].
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Depression was measured using the Beck depression inventory for primary care (BDI-PC). The
BDI-PC consists of seven items scored on a four-point Likert scale (0–3). Scores range from 0 to 21
points, and a higher score indicates more clinical symptoms of depression. A score of ≥ 4 points was
used to categorize patients as ‘depressed’ and signify that a detailed psychiatric evaluation may be
warranted [36,42].
2.3.4. Collection of Post-PR Data
The following post-treatment data were collected in the week after discharge: weight, FFMi,
BMI, lung function, exercise tolerance, quadriceps muscle strength, anxiety, and health status (NCSI;
including subjective fatigue, dyspnoea and depression).
2.4. Statistical Analysis
Statistical analyses were conducted using SPSS v25.0 (IBM Corp., Armonk, NY, USA). Data were
presented as mean ± standard deviation (SD), or frequencies and proportions, where appropriate. A
‘responder analysis’ was conducted to determine differences in baseline characteristics and impact of
PR between ‘responders’ and ‘non-responders’ on fatigue. Patients with normal fatigue at baseline
where excluded from the ‘responder analysis’. Differences between ‘responders’ and ‘non-responders’
on fatigue upon baseline characteristics and impact on PR (change scores following PR) were analysed
by unpaired t-test or the non-parametric pendant (Mann–Whitney U test) for continuous data, where
appropriate. Categorical data were analysed with the chi-square test or Fisher’s exact test, where
appropriate. If significant, a post-hoc comparison of the chi-square test was performed, and significant
Bonferonni-adjusted p-values were generated as correction for multiple comparison. To examine the
effectiveness of the PR, paired t-tests (or Wilcoxon signed-rank tests) were used to compare pre- and
post-PR data, where appropriate. Bivariate correlations were assessed by Pearson or Spearman’s rank
correlation, where appropriate, to assess the relationship between change in fatigue and change in
possible contributing factors to fatigue. Cohen’s d was used to interpret the effect size of correlation
coefficients. A correlation coefficient of 0.10~<0.30 represents a weak/small association, 0.30~<0.50 is
considered a moderate correlation; and ≥0.50 is thought to represent a large/strong correlation [43].
Change scores (∆) were calculated as post-PR scores minus pre-PR scores. The level of significance
was set at 0.01 for all statistical tests (two-tailed).
3. Results
3.1. Patient Characteristics
Between July 2002 and July 2013, 459 COPD patients completed the inpatient PR, of whom 446
patients were eligible for inclusion. Reasons for exclusion were absence of data regarding lung function
and weight at baseline (n = 10 and n = 3, respectively). Most patients with COPD had a low level of
education, were former smokers, had (very) severe COPD, and reported one or more comorbidities.
Additionally, 78.4% had a 6MWD < 70% predicted, indicating an impairment in exercise tolerance [25].
At the start of the PR, 93.5% (417 out of 446) reported (abnormal) fatigue, 18.6% mild fatigue, and 74.9%
severe fatigue. Clinical indications for anxiety and depression were found in 21.6% and 38.6% of the
patients, respectively. Table 2 shows these characteristics in detail.
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Table 2. Baseline characteristics of all eligible chronic obstructive pulmonary disease (COPD) patients
referred for pulmonary rehabilitation (PR) (n = 446).
Demographical Features
Age, y 60.5 ± 8.8
Male, n (%) 238 (53.4)
Education level, low/middle/high, n a 229/151/60
Tobacco use, b non-/ex-/smoker, n 23/376/47
COPD diagnosis > 10 years, n (%) c 145 (32.5)
≥1 self-reported comorbidity, n (%) b 336 (76.2)
Clinical Features
BMI, kg/m2 25.9 ± 5.5
BMI classification, Uw/No/Ow/Ob, n 69/157/140/80
FEV1, L 1.2 ± 0.5
FEV1, % predicted 42.5 ± 17.7
GOLD grade, I/II/III/IV, n 17/99/210/120
6MWD, m d 383.2 ± 105.8
6MWD, % predicted d 58.2 ± 15.4
<70% predicted, n (%) 290 (78.4)
Anxiety (SCL-90-A, 10–50), p b 17.6 ± 7.2
Anxiety score ≥ 23, n (%) 95 (21.6)
Health Status (NCSI)
Fatigue (CIS-Fatigue, 8–56), p 41.9 ± 9.3
Fatigue severity, normal/mild/severe, n 29/83/334
Dyspnoea (Dyspnoea VAS, 0–10), p 5.8 ± 1.9
HRQoL (2-10) *, p 5.8 ± 1.7
Depression (BDI-PC, 0–21) *, p 3.4 ± 3.0
Depression score ≥ 4, n (%) 172 (38.6)
Data is presented as mean ± SD, or number (%). * The Beck depression inventory for primary care (BDI-PC) is part
of the domain ‘HRQoL’ (health-related quality of life). Alphabetic characters in superscript indicates a sample size
deviant from n = 446, with a n = 440, b n = 441, c n = 403, d n = 370. Abbreviations: n, number; BMI, body mass
index; Uw, underweight; No, normal weight; Ob, obese; Ow, overweight; FEV1, forced expiratory volume in first
second; L, litre; GOLD, global initiative for chronic obstructive lung disease; 6MWD, six minute walking distance
test; m, metre; SCL-90-A, 90-item symptom checklist—subscale anxiety; p, points; NCSI, Nijmegen clinical screening
instrument; CIS-Fatigue, checklist individual strength—subscale subjective fatigue; Dyspnoea VAS, dyspnoea visual
analogue scale; HRQoL, health-related quality of life; BDI-PC, Beck depression inventory for primary care.
3.2. Effects of PR on Subjective Fatigue
Mean CIS-Fatigue score improved significant and clinically relevant compared to baseline (−10.4
± 11.7 points; p < 0.001: Online Table S1). The prevalence of severe fatigue decreased from 74.9% at the
start of the PR to 33.0% after the PR programme. In addition, the proportion of patients with normal
fatigue increased from 6.5% to 33.4%. From the patients with severe fatigue at baseline, 37.1% (124
out of 334) reported severe fatigue after PR. The proportion of patients with normal, mild, and severe
fatigue before and after PR, the flow of patients following PR, and the direction of change can be found
in Figure 1.
3.3. Effects of PR on Other Outcome Measures
PR significantly improved exercise tolerance (6MWD, +57.6 ± 73.2 m), quadriceps muscle strength
(+26.0 ± 64.0 Nm), anxiety (−3.0 ± 5.7 points), and health status measured with the NCSI (all p-values
< 0.001), including depression (−1.5 ± 2.6 points) and dyspnoea (−1.1 ± 2.1 points). Please see Online
Table S1 for all details.
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normal fatigue and mild fatigue at baseline were classified as responders on fatigue (3.4% and 30.1%,
respectively), in comparison to 62.3% of the initial severe fatigue group (Figure 2).
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3.6. Responder Analysis
Results of the responder analysis (n = 417) upon differences between responders and
non-responders on fatigue at baseline can be found in Table 3. At baseline, fatigue and HRQoL
were worse in responders versus non-responders. Baseline demographics, body composition, lung
function, exercise tolerance, quadriceps muscle strength, anxiety, and health status (including dyspnoea
and depression) were comparable.
Table 3. Baseline characteristics of COPD patients stratified for response of fatigue after PR (responder
analysis, n = 417).
Responders 1
(n = 233)
Non-Responders 2
(n = 184)
p-Value
Demographical Features
Age, y 59.5 ± 8.8 61.8 ± 8.6 0.011
Male, n (%) 115 (49.4) 106 (57.6) 0.094
Tobacco use a non-/ex-/smoker, n 7/194/29 10/156/17 0.291
COPD diagnosis > 10 years, n (%) b 82 (38.7) 54 (32.7) 0.233
≥1 self-reported comorbidity, n (%) a 178 (77.4) 142 (77.6) 0.961
Clinical Features
BMI, kg/m2 26.1 ± 5.6 25.9 ± 5.4 0.879
FFMi, kg/m2 c 16.4 ± 2.2 16.7 ± 2.4 0.220
FEV1, L 1.3 ± 0.6 1.2 ± 0.5 0.217
FEV1, % predicted 44.0 ± 18.0 41.4 ± 17.2 0.102
GOLD grade I/II/III/IV, n 10/58/106/59 6/36/91/51 0.543
6MWD, m d 391.4 ± 105.0 369.0 ± 104.8 0.051
6MWD, % predicted d 59.4 ± 14.9 56.4 ±16.1 0.072
<70 % predicted, n (%) 151 (76.7) 122 (81.9) 0.238
Quadriceps muscle strength, Nm e 294.5 ± 102.9 284.9 ± 98.4 0.515
Anxiety (SCL-90-A, 10–50), p f 17.7 ± 7.0 18.1 ± 7.5 0.620
Anxiety score ≥ 23, n (%) 48 (20.9) 44 (24.3) 0.406
NCSI—Symptoms
Subjective dyspnoea, p # 13.1 ± 3.8 13.3 ± 3.7 0.868
Dyspnoea (Dyspnoea VAS, 0–10) p # 4.3 ± 1.9 5.4 ± 1.9 0.519
Dyspnoea emotions 13.0 ± 3.9 13.0 ± 4.1 0.926
Fatigue (CIS-Fatigue, 8–56), p 45.4 ± 7.3 40.5 ± 7.8 <0.001
Mild fatigue, n (%) 25 (10.7) 58 (31.5) }
<0.001Severe fatigue, n (%) 208 (89.3) 126 (68.5) }
NCSI—Quality of Life
General QoL, p 28.0 ± 14.8 26.8 ± 14.3 0.615
HRQoL (2–10), p * 6.1 ± 1.6 5.7 ± 1.7 0.004
Depression (BDI-PC, 0–21), p * 3.6 ± 3.1 3.3 ± 2.9 0.384
Depression score ≥ 4, n (%) 93 (39.3) 74 (40.2) 0.950
Satisfaction with relations, p 4.0 ± 1.8 3.8 ±1.9 0.056
NCSI—Functional Impairment
Subjective impairment, p 16.5 ± 5.2 16.9 ± 5.1 0.555
Behaviour impairment, p 27.1 ± 13.7 28.1 ± 14.3 0.517
Data is presented as mean ± SD, or number (%). p-value in bold indicates a significant difference. } indicates
significant post-hoc pairwise comparison of the chi-square test (Bonferonni adjusted p-value < 0.01). * The BDI-PC
is part of the subdomain ‘HRQoL’ of the NCSI. # The Dyspnoea VAS is part of the subdomain ‘subjective dyspnoea’
of the NCSI. 1 ∆fatigue ≥ 10 points. 2 ∆fatigue < 10 points. Alphabetic characters in superscript indicate a sample
size deviant from n = 417, with a n = 413 (responders and non-responders respectively, 230 and 183), b n = 377 (resp.,
212 and 165), c n = 396 (resp., 225 and 171), d n = 346 (resp., 197 and 149), e n = 371 (resp., 201 and 170), and f n = 411
(resp., 230 and 181). Abbreviations: COPD, chronic obstructive pulmonary disease; PR, pulmonary rehabilitation;
n, number; BMI, body mass index; FFMi, fat-free mass index; FEV1, forced expiratory volume in first second; L,
litre; GOLD, global initiative for chronic obstructive lung disease; 6MWD, six minute walking distance test; m,
metre; Nm, Newton meter; SCL-90-A, 90-item symptom checklist—subscale anxiety; p, points; NCSI, Nijmegen
clinical screening instrument; Dyspnoea VAS, dyspnoea visual analogue scale; CIS-Fatigue, checklist individual
strength—subscale subjective fatigue; QoL, quality of life; HRQoL, health-related quality of life; BDI-PC, Beck
depression inventory for primary care.
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Responders on fatigue showed a significantly greater improvement in anxiety, depression,
dyspnoea, exercise tolerance, and the majority of all health status parameters (with the exception of
behaviour impairment) compared to non-responders (all p-values ≤ 0.01; Table 4).
Table 4. Change scores after PR of patients with COPD stratified for response of fatigue.
Responders 1
(n = 233)
Non-Responders 2
(n = 184)
p-Value
Clinical Features
∆BMI, kg/m2 a −0.0 ± 1.4 −0.1 ± 1.3 0.914
∆FFMi, kg/m2 b 0.3 ± 1.0 −0.1 ± 1.3 0.012
∆FEV1, L c 0.1 ± 0.3 0.0 ± 0.3 0.572
∆6MWD, m d 70.7 ± 74.4 38.3 ± 70.3 0.001
∆Quadriceps muscle strength, Nm e 25.5 ± 62.0 26.5 ± 68.7 0.901
∆Anxiety (SCL-90-A, 10–50), p f −4.1 ± 5.5 −1.8 ± 6.0 <0.001
NCSI—Symptoms
∆Subjective dyspnoea, p # g −4.2 ± 4.2 −2.1 ± 4.3 <0.001
∆Dyspnoea (Dyspnoea VAS, 0–10), p # g −1.5 ± 2.1 −0.6 ± 2.0 <0.001
∆Dyspnoea emotions, p h −2.6 ± 3.9 −1.2 ± 3.7 <0.001
∆Fatigue (CIS-Fatigue, 8–56) −19.2 ± 7.2 −1.7 ± 6.4 <0.001
NCSI—Quality of Life
∆General QoL, p i −10.3 ± 12.3 −5.4 ± 12.0 <0.001
∆HRQoL, p * i −2.5 ± 1.9 −1.1 ± 1.8 <0.001
∆Depression (BDI-PC, 0–21), p * −2.1 ± 2.6 −1.0 ± 2.6 <0.001
∆Satisfaction with relationship, p −0.9 ± 1.9 −0.2 ± 2.3 0.003
NCSI—Functional Impairment
∆Subjective impairment, p −4.8 ± 5.6 −1.9 ± 5.0 <0.001
∆Behaviour impairment, p −2.9 ± 13.6 −0.6 ± 16.0 0.106
Data is presented as mean ± SD, or number (%). p-value in bold indicates a significant difference. * The BDI-PC is
part of the subdomain ‘HRQoL’ of the NCSI. # The Dyspnoea VAS is part of the subdomain ‘subjective dyspnoea’ of
the NCSI. 1 ∆fatigue ≥ 10 points. 2 ∆fatigue < 10 points. Alphabetic characters in superscript indicates a sample
size deviant from n = 417, with a n = 363 (responders and non-responders respectively, 208 and 155), b n = 287
(resp., 167 and 120), c n = 347 (resp., 199 and 148), d n = 255 (resp. 155 and 100), e n = 291 (resp., 163 and 128), f n
= 405 (resp., 227 and 178), g n = 416 (resp., 232 and 184), h n = 412 (resp., 229 and 183), and i n = 416 (resp., 233
and 183). Abbreviations: COPD, chronic obstructive pulmonary disease; PR, pulmonary rehabilitation; n, number;
∆, post-PR score minus pre-PR score; BMI, body mass index; FFMi, fat-free mass index; FEV1, forced expiratory
volume in first second; L, litre; 6MWD, six minute walking distance test; m, metre; Nm, Newton meter; SCL-90-A,
90-item symptom checklist—subscale anxiety; p, points; NCSI, Nijmegen clinical screening instrument; Dyspnoea
VAS, dyspnoea visual analogue scale; CIS-Fatigue, checklist individual strength—subscale subjective fatigue; QoL,
quality of life; HRQoL, health-related quality of life; BDI-PC, Beck depression inventory for primary care.
4. Discussion
This is the first study to show that about half of the patients with COPD have a clinically relevant
improvement in fatigue following PR, and that the responders on fatigue (patients with ∆CIS-Fatigue
≥ 10 points) also had greater improvements in exercise tolerance, anxiety, and health status (including
depression, dyspnoea, and HRQoL) compared to non-responders.
The prevalence of fatigue in patients with COPD is high at the start of an inpatient PR programme.
Approximately three-quarters of all patients referred for PR suffered from severe fatigue at baseline.
These findings are in line with findings of previous studies in patients referred for PR [44,45]. Fortunately,
an interdisciplinary PR programme reduces fatigue in patients with COPD, as already found by Peters
and colleagues [19] and others (all relative small samples) [46–50]. Interestingly, about half of the
COPD patients with mild or severe fatigue who completed the 12-week inpatient PR programme
(55.9%) showed a clinically relevant improvement in fatigue. This was even higher in patients with
severe fatigue (62.3%), and cannot be attributed to regression to the mean only. Indeed, mild or severe
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fatigue for sure will not improve following usual COPD care. Several studies have already reported
that fatigue increases in patients with COPD, despite optimal COPD care [13,19,51,52]. Therefore, these
findings emphasize that complaints of mild or severe fatigue may be a reason for referral to PR [53]. In
total, 30 patients showed an increase in level of fatigue following PR (Figure 1). This is remarkable and
several possible explanations can be given. First of all, this increase can be attributed to regression to
the mean, whereas most of these patients scored relatively low at baseline. Other explanations are
physical deterioration due to a COPD-related exacerbation during PR or an increase in fatigue as result
of an awareness-raising process/change in coping style which occurred during PR [54].
Several weak but significant correlations were found between change in fatigue and change in
possible contributing factors to fatigue following PR (such as anxiety, depression, exercise tolerance,
dyspnoea, and others). Two other small-scale studies found comparable results for depression, exercise
tolerance, and QoL, but not for anxiety [47,55]. Fatigue in COPD is above all the result of complex
interactions between physiological, behavioural, systematic, and psychological processes which are
different from person to person [56,57]. This clarifies the weak to moderate, but significant correlations
found. Based on the currently available data, it is difficult to understand which PR ingredients
have contributed to the reduction in fatigue [14]. Moreover, the current study design does also not
allow us to derive causality between the changes in fatigue and the changes in anxiety, depression,
dyspnoea, exercise tolerance, and health status. Furthermore, findings of our study illustrated that
responders on fatigue achieved greater improvement on other outcomes in PR. The role of fatigue (and
its improvement) in the rehabilitation process and outcomes of PR needs to be further investigated.
PR seems to be an effective strategy to reduce fatigue in the majority of COPD patients, whereas
previous studies showed that the mean fatigue did not decrease after six months and after one year of
usual care [19,51]. Indeed, patients with severe fatigue at baseline benefit the most in terms of fatigue
(Figure 2). The effectiveness of the PR programme upon fatigue may even be underestimated, as
patients with normal fatigue are included in the study because of a regression to the mean/floor effect
as there is less room to improve and a limiting ability to detect response on fatigue in these patients [58].
Yet, one-third of patients with severe fatigue at baseline were still classified as non-responders on fatigue,
despite their room for improvement (Figure 2). Non-responders on fatigue were also poor responders
on the PR programme in general, regardless of comparable exercise tolerance, dyspnoea, clinical
symptoms of anxiety and depression, and health status at the start of the inpatient PR programme.
Therefore, these patients may require additional (or more intensified) interventions to reduce fatigue
(and its possible contributing factors) [56,59]. Given the relevance of fatigue in patients with COPD, it
is important to optimize PR to reduce fatigue in these patients. Our results show that identification
of potential responders and non-responders on fatigue at baseline is difficult. Besides differences
on fatigue and HRQoL, no other differences were found at baseline (Table 3). Early detection of
non-responders during PR (by mid-term evaluation of fatigue and its perpetuating factors) may offer
opportunities to optimize PR for these patients.
Strengths, Limitations, and Clinical Implications
This study investigates fatigue in COPD, a patient-initiated and clinically relevant topic, that
despite the high prevalence (and relevance) of fatigue has been neglected in research [12,53]. All
patients underwent a broad health status assessment (including anxiety and depression) that resulted
in an individualised treatment plan followed by an interdisciplinary PR programme. The current
findings demonstrate that fatigue is highly prevalent in COPD patients referred for PR, and emphasize
the importance of the use of a fatigue questionnaire (such as the CIS-Fatigue). This study is the first that
has included a broad range of possible contributing factors to fatigue. Fatigue has a substantial impact
on patients with COPD, and is therefore an important target for treatment [3,5,6]. Our results show
that an interdisciplinary PR programme reduces fatigue in patients with COPD, in which usual care
(optimal COPD care) does not succeed. To date, a holistic and strongly individualised approach seems
to be the most appropriate manner to treat fatigue in COPD because of its multifactorial nature [8,15,53].
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Not only an impaired exercise tolerance or high symptom burden, but also severe fatigue may be
an indication for PR. This secondary, retrospective analysis of a large prospective cohort has also
several limitations. First of all, this study design may affect the validity of the results. Second, several
systematic, behavioural, and demographic factors, such as data regarding a patient’s exacerbation rate
(previous 12 months), physical activity, sleep quality, medication intake, coping style, and motivation
were not available in the current study. These variables may have influenced patients’ potential to
achieve a MCID on fatigue. Third, it is suspected that less-motivated patients (but also the more severe
or unstable patients) were not represented in this analysis, since participation in the PR was voluntary.
Fourth, the influence of fatigue on PR completion cannot be determined, whereas only data of PR
completers were available. It is suspected that fatigue may have an influence on PR completion [57].
Fifth, data was collected over a period of 11 years (July 2002 to July 2013), and PR has optimized over
the years with greater improvements as a consequence. However, no differences in change scores were
found between the 2002 and 2013 cohort upon any variable (excluding dyspnoea emotions).
5. Conclusions
Fatigue is an important and highly prevalent extra-pulmonary symptom in patients with COPD.
An inter-disciplinary PR programme reduces fatigue in COPD, and has a strong beneficial effect on
fatigue (improvement ≥MCID) in more than half the COPD patients who complete PR (even with
severe or very severe COPD). Identification of prognostic factors for a clinically relevant improvement
on fatigue following PR was not possible. Indeed, responders on fatigue had worse fatigue and
HRQoL scores at baseline. Responders on fatigue were likely to be responders on other outcomes in
PR. Future research should focus on identification of precipitating and perpetuating factors of fatigue
and optimizing PR for those non-responders on fatigue with mild and severe fatigue at baseline.
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